StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research report released on Monday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Down 3.2 %
Evoke Pharma stock opened at $5.65 on Monday. The firm’s 50 day simple moving average is $4.99 and its 200 day simple moving average is $5.52. Evoke Pharma has a 1-year low of $3.54 and a 1-year high of $17.88. The firm has a market capitalization of $4.64 million, a PE ratio of -0.35 and a beta of 0.36.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The business had revenue of $2.55 million during the quarter. Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Recommended Stories
- Five stocks we like better than Evoke Pharma
- How Technical Indicators Can Help You Find Oversold Stocks
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- There Are Different Types of Stock To Invest In
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Bank Stocks – Best Bank Stocks to Invest In
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
